A.L. PHARMA ANNOUNCES FDA APPROVAL OF BETAMETHASONE DIPROPIONATE OINTMENT.FORT LEE, NJ, Sept. 12, 1995--(BUSINESS WIRE)--A.L. Pharma Inc. (NYSE NYSE See: New York Stock Exchange :ALO) today announced that its U.S. Pharmaceuticals Division, which manufactures and markets specialty generic pharmaceuticals, has received approval from the Food and Drug Administration to manufacture and market Betamethasone betamethasone /be·ta·meth·a·sone/ (ba?tah-meth´ah-son) a synthetic glucocorticoid, the most active of the antiinflammatory steroids; used topically as the benzoate, dipropionate, or valerate salts as an antiinflammatory, topically or Dipropionate Ointment ointment /oint·ment/ (oint´ment) a semisolid preparation for external application to the skin or mucous membranes, usually containing a medicinal substance. oint·ment n. USP USP - unique sales point , (Augmented) 0.05% (base). Betamethasone Dipropionate Ointment is the generic equivalent of the prescription branded product Diprolene Ointment, 0.05% (base) which has a branded market of approximately $15 million. The Company's U.S. Pharmaceuticals Division plans to begin marketing this product early in the fourth quarter of this year. This is the first FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved generic equivalent of Diprolene Ointment. A.L. Pharma is a multinational pharmaceutical company developing, manufacturing and marketing specialty generic and proprietary human pharmaceuticals and animal health products. A.L. Pharma resulted from the combination of the human pharma- ceutical and animal businesses of Apothekernes Laboratorium A.S of Oslo, Norway with A. L. Laboratories, Inc. on October 3, 1994. CONTACT: Iris Daniels Investor Relations Investor relations The process by which the corporation communicates with its investors. Mlanager A.L. Pharma Inc. (201) 947-7774 OR Investor Relations Contact: Donna Stein/Sue Rodney Morgen-Walke Associates, Inc. (212) 850-5600 OR Press Contact: Michelle Zawrothy Morgen-Walke Associates, Inc. (212) 850-5631 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion